Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer
Open Access
- 31 July 2004
- journal article
- clinical trial
- Published by Elsevier BV in European Journal of Cancer
- Vol. 40 (11), 1704-1712
- https://doi.org/10.1016/j.ejca.2004.03.025
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastasesAnnals Of Oncology, 2003
- Health-Related Quality-of-Life Measurement in Randomized Clinical Trials in Breast Cancer--Taking StockJNCI Journal of the National Cancer Institute, 2003
- Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasisBreast Cancer Research and Treatment, 2000
- Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone MetastasesThe New England Journal of Medicine, 1996
- Bisphosphonates: mechanisms of action.JCI Insight, 1996
- Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injectionJournal of Bone and Mineral Research, 1996
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI Journal of the National Cancer Institute, 1993
- Bone metastasis in breast cancerAnti-Cancer Drugs, 1992
- The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancerEuropean Journal of Cancer and Clinical Oncology, 1991
- Assessment of Response to TreatmentPublished by Springer Science and Business Media LLC ,1991